Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Trial of PXVX0317 Chikungunya Virus-Like Particle Vaccine in Healthy Adults and Adolescents
2023-001124-42Phase 3
- Sponsor
- Bavarian Nordic
- Start
- Feb 2024
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Chikungunya (CHIKV) comparing PXVX0317 with Placebo (2 arms). Primary endpoint: Solicited adverse events through Day 8.
02
Drugs
CHIKV VLP vaccine
03
Conditions
Chikungunya (CHIKV)
Beyond the preview
Go deeper on 2023-001124-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-001124-42.